CD83抗体—艾普蒂

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human gastric cancer tissue using P09457(CD83 Antibody) at dilution 1/170. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human tonsil tissue using P09457(CD83 Antibody) at dilution 1/170. (Original magnification: ×200)    

  
  

CD83 is a transmembrane glycoprotein primarily expressed on the surface of mature dendritic cells (DCs), key regulators of adaptive immunity. First identified in the 1990s, CD83 plays a critical role in immune modulation, particularly in T-cell activation and immune tolerance. Its expression is tightly regulated during DC maturation, making it a reliable marker for distinguishing mature DCs from their immature counterparts. Structurally, CD83 consists of an extracellular Ig-like domain, a transmembrane region, and a short cytoplasmic tail. A soluble form (sCD83) is also generated through proteolytic cleavage or alternative splicing, which exhibits immunosuppressive properties.

CD83 antibodies are essential tools in immunological research and therapeutic development. They are widely used to study DC-T cell interactions, immune synapse formation, and mechanisms underlying autoimmune diseases, transplantation tolerance, and cancer immunotherapy. For instance, agonistic anti-CD83 antibodies have shown potential in enhancing DC-mediated immune responses, while blocking antibodies or sCD83 fusion proteins may suppress aberrant immune activation in conditions like rheumatoid arthritis or graft-versus-host disease. Commercial CD83 antibodies (e.g., clone HB15e for flow cytometry, HI83a for functional studies) enable DC phenotyping in human and murine models. Ongoing research explores CD83-targeting strategies for modulating immune responses, balancing its dual roles in immune activation and tolerance induction.